Article Sidebar

PDF
Date Published: 12/01/2022
Abstract Views: 313
Views PDF: 189
DOI: https://doi.org/10.51298/vmj.v509i1.1700
Issue
Vol. 509 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Thanh, N. ., Quốc Tùng, M. ., & Thị Phúc, H. . (2022). EVALUATION OF TREATMENT OUTCOMES FOR INTRAVITREAL RANIBIZUMAB IN DIABETIC MACULAR EDEMA. Vietnam Medical Journal, 509(1). https://doi.org/10.51298/vmj.v509i1.1700

EVALUATION OF TREATMENT OUTCOMES FOR INTRAVITREAL RANIBIZUMAB IN DIABETIC MACULAR EDEMA

Nguyễn Thị Thanh1,, Mai Quốc Tùng2, Hoàng Thị Phúc3
1 Hanoi Eye Hospital
2 Hanoi Medical University
3 Vietnam Ophthalmological Society

Main Article Content

Abstract

Purpose: toevaluate the treatment outcomes of intravitreal Ranibizumab injection for diabetic macular edema in Ha Noi Eye Hospital. Subjectives and Methods: 30 eyes of 30 patients treated with intravitreal Ranibizumab injection for diabetic macular edema included. Methods: prospectively interventional non-control study. Results: Pattern macular edema on OCT at baseline: 13/30 (43,3%) eyes with diffuse macular edema, 9/30 (33,0%) eyes with cystoid macular edema, 8/30 (26,7%) eyes with serous retinal detachment. The visual acuity improvement(logMAR) 3 month vs baseline is statistically significant (p<0,001). The reduction of CRT from baseline to 3 month later is statistically significant, p<0,001. Conclusion: Visual acuity and CRT improvedsteadilyafter 3 intravitreal Ranibizumab injections for diabetic macular edema: best corrected visual acuity (logMAR) improve from 0,9 at baseline to 0,64 after 3 month (p<0,001); and CRT reduces from 453,3 µm at baseline to 314,8 µm after 3 month, (p<0,001).

Article Details

Keywords

diabetic macular edema, central macular thickness

References

1. Lai T-T. Treatment outcomes and Predicting factors for diabetic macular edema treated with ranibizumab- one- year real - life results in Taiwan. Journal of the Formosan Medical Association. 2019;118(1):194-202.
2. Kyung Soon Seo MD. Visual and Morphologic outcomes of intravitreal Ranibizumab for Diabetic Macular Edema Based on optical Coherence Tomography Patterns. Retina. 2016:588-595.
3. Channa R, Sophie R, Khwaja AA, et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond). 2014;28(3):269-278.
4. Berger A, Sheidow T, Cruess AF, Arbour JD, Courseau AS, de Takacsy F. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME. Can J Ophthalmol. 2015;50(3):209-216.
5. Pascale Massin M, PhD. Safty and Efficacy of Ranibizumab in Diabetic Macular Edema Diabetes Care. 2010;33:2399-2405.
6. Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952.
7. Campos A. Evaluation of markers of outcome in realworld treatment of diabetic macular edema. Eye and Vision. 2018.